Role of taxanes in pancreatic cancer

Carmen Belli, Stefano Cereda, Michele Reni

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

Original languageEnglish
Pages (from-to)4457-4465
Number of pages9
JournalWorld Journal of Gastroenterology
Volume18
Issue number33
DOIs
Publication statusPublished - 2012

Fingerprint

Taxoids
gemcitabine
Pancreatic Neoplasms
Combination Drug Therapy
Therapeutics
Drug Therapy
Neoplasms

Keywords

  • ABI-007
  • Advanced disease
  • Chemotherapy
  • Drug combinations
  • Metastatic disease
  • Pancreatic cancer
  • Radiotherapy
  • Taxanes

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Role of taxanes in pancreatic cancer. / Belli, Carmen; Cereda, Stefano; Reni, Michele.

In: World Journal of Gastroenterology, Vol. 18, No. 33, 2012, p. 4457-4465.

Research output: Contribution to journalArticle

Belli, Carmen ; Cereda, Stefano ; Reni, Michele. / Role of taxanes in pancreatic cancer. In: World Journal of Gastroenterology. 2012 ; Vol. 18, No. 33. pp. 4457-4465.
@article{db059b92a9eb400c834b343345105824,
title = "Role of taxanes in pancreatic cancer",
abstract = "Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.",
keywords = "ABI-007, Advanced disease, Chemotherapy, Drug combinations, Metastatic disease, Pancreatic cancer, Radiotherapy, Taxanes",
author = "Carmen Belli and Stefano Cereda and Michele Reni",
year = "2012",
doi = "10.3748/wjg.v18.i33.4457",
language = "English",
volume = "18",
pages = "4457--4465",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "33",

}

TY - JOUR

T1 - Role of taxanes in pancreatic cancer

AU - Belli, Carmen

AU - Cereda, Stefano

AU - Reni, Michele

PY - 2012

Y1 - 2012

N2 - Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

AB - Pancreatic cancer is one of the most deadly cancers and is characterized by a poor prognosis. Single agent gemcitabine, despite its limited activity and modest impact on disease outcome, is considered as the standard therapy in pancreatic cancer. Most of the combination regimens used in the treatment of this disease, also including the targeted agents, did not improve the outcome of patients. Also, taxanes have been tested as single agent and in combination chemotherapy, both in first line and as salvage chemotherapy, as another possible option for treating pancreatic cancer. The inclusion of taxanes in combination with gemcitabine as upfront therapy obtained promising results. Accordingly, taxanes, and above all, new generation taxanes, appear to be suitable candidates for further testing to assess their role against pancreatic cancer in various clinical settings.

KW - ABI-007

KW - Advanced disease

KW - Chemotherapy

KW - Drug combinations

KW - Metastatic disease

KW - Pancreatic cancer

KW - Radiotherapy

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=84867725219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867725219&partnerID=8YFLogxK

U2 - 10.3748/wjg.v18.i33.4457

DO - 10.3748/wjg.v18.i33.4457

M3 - Article

VL - 18

SP - 4457

EP - 4465

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 33

ER -